Clinical Pharmacists role in the therapeutic management of COVID-19 patients in Morocco

Main Article Content

Aicha Chaibi, PharmD Mrani Alaoui Amal, PharmD Lasri Fatima-Zahra, PharmD Abouqal Redouane, MD Madani Naoufel, MD


In Morocco, the first case of a respiratory illness due to a new form of coronavirus, the SARS-CoV-2, was registered on the evening of March 1st according to the Ministry of Health.

As the pandemic threatened to develop, the Technical and Scientific Committee of the Ministry of Health decided to prescribe a combination of chloroquine/ hydroxychloroquine with azithromycin for all symptomatic patients confirmed COVID-19 in spite of the fact that the combination has not been approved for COVID-19 indication.

This off-label use exposes to an iatrogenic risk. The aim of this paper is to establish an integrated strategy for pharmaceutical care services which a focus on COVID-19 hospitalized patients (excluding patients in intensive care units) and Clinical Pharmacists, in order to improve COVID-19 patients’ outcome, reduce mortality and drug-related iatrogenia and facilitate pandemic control.

Clinical Pharmacists have played an important role in optimizing the management of COVID-19 patients within the hospital structure from the admission to the discharge of patients. Clinical Pharmacists participate in the therapeutic decision, manage drug Interactions and adjust therapy for special risk population and patients with combined underlying diseases. They also monitor and evaluate medication safety (Medication errors, drug interactions and adverse drug reactions). They have developed practical help sheets that constitute a reliable, and “easy to search” database.

During this crisis, Clinical Pharmacists have not only developed protocols and practical sheets but they have also been the guarantors of the rational use of drugs, providing medical advice to frontline medical staff, especially regarding off label drugs.

Keywords: Clinical Pharmacist, Hydroxychloroquine, Azithromycin, COVID-19, Iatrogenia, Drug interactions

Article Details

How to Cite
CHAIBI, Aicha et al. Clinical Pharmacists role in the therapeutic management of COVID-19 patients in Morocco. Medical Research Archives, [S.l.], v. 8, n. 10, oct. 2020. ISSN 2375-1924. Available at: <>. Date accessed: 12 apr. 2024. doi:


1. Li, H., et al., Fighting against COVID-19: Innovative strategies for clinical pharmacists. Res Social Adm Pharm, 2020.
2. Minstère de la santé marocain :Le Maroc annonce l'enregistrement du premier cas du nouveau Coronavirus 2020és.aspx?communiqueID=355 .Accessed date 15 May 2020.
3. Song, Z., et al., Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience. Res Social Adm Pharm, 2020.
4. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England), 2020. 395(10223): p. 507-513.
5. Fang, L., G. Karakiulakis, and M. Roth, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet. Respiratory medicine, 2020. 8(4): p. e21-e21.
6. Lauer, S.A., et al., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med, 2020. 172(9): p. 577-582.
8. JACCP, Roles of the clinical pharmacist during the COVID-19 pandemic. journal of american college of clinical pharmacy, 22 March 2020: p. 3.
9. Mrani Alaoui, A., et al., Interventions pharmaceutiques dans un service d’urgences médicales : résultats de l’expérience d’un pays du Maghreb. Le Pharmacien Hospitalier et Clinicien, 2020.
10. Fatima-Zahra, B., et al., Administration et préparation des antibiotiques injectables: Analyse des pratiques en réanimation chirurgicale. Le Pharmacien Hospitalier et Clinicien, 2020.
11. Moukafih, B., et al., Impact of clinical pharmacy services in a hematology/oncology ward in Morocco. Journal of Oncology Pharmacy Practice, 2020: p. 1078155220919169.
12. El Marnissi, S., et al., Analyse du risque infectieux autour du patient dans l’unité d’hémodialyse de l’hôpital Ibn Sina de Rabat par application de la méthode d’analyse des modes de défaillance, de leurs effets et de leur criticité. Néphrologie & Thérapeutique, 2020. 16(2): p. 105-117.
13. Saqrane, S. and M.A. El Mhammedi, Review on the global epidemiological situation and the efficacy of chloroquine and hydroxychloroquine for the treatment of COVID-19. New microbes and new infections, 2020. 35: p. 100680-100680.
14. Quiros Roldan, E., et al., The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? Pharmacological research, 2020. 158: p. 104904-104904.
15. Choudhary, R. and A.K. Sharma, Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New Microbes and New Infections, 2020. 35: p. 100684.
16. Quiros Roldan, E., et al., The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis? Pharmacol Res, 2020. 158: p. 104904.
17. Chen, Z., et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv, 2020: p. 2020.03.22.20040758.
18. Taccone, F.S., J. Gorham, and J.-L. Vincent, Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. The Lancet Respiratory Medicine.
19. Singh, A.K., et al., “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020. 14(4): p. 589-596.
20. Alexander, P.E., et al., COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. J Clin Epidemiol, 2020.
21. Chorin, E., et al., QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. Heart Rhythm, 2020.
22. Bessière, F., et al., Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. JAMA cardiology, 2020: p. e201787.
23. Mercuro, N.J., et al., Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, 2020.
24. Gautret, P., et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis, 2020. 34: p. 101663.
25. Ministère de la santé Marocain: circulaire N°22 prescription de la chloroquine et dispensation de la CHLOROQUINE et de l'HYDOXYCHLOROQUINE au niveau des établissements de soins 23 Mars 2020.
26. Mehra, M.R., et al., Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet, 2020.
27. CREDIBLEMEDS: QT drugs lists .Accessed Mars 2020
28. Han, C., et al., Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol, 2020.
29. Base de donnés thériaque:monographie plaquenil 200 mg updating 30 March 2020 .thé accessed April 2020
30. Rossi, M. and G. Giorgi, Domperidone and long QT syndrome. Curr Drug Saf, 2010. 5(3): p. 257-62.
31. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. Ameican College of Cardiology, Mar 29, 2020.
32. Ying, W., Y. Qian, and Z. Kun, Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic. Res Social Adm Pharm, 2020.
33. Gross, A.E., et al., The Effect of a Piperacillin/Tazobactam Shortage on Antimicrobial Prescribing and Clostridium difficile Risk in 88 US Medical Centers. Clin Infect Dis, 2017. 65(4): p. 613-618.